当前位置: 首页 > 期刊 > 《中国实用医药》 > 202030
编号:13796705
应用改良Bu/Cy/Mel预处理方案的单倍体移植提高单中心68例难治复发急性髓系白血病的临床疗效(3)
http://www.100md.com 2020年10月25日 《中国实用医药》 202030
     參考文献

    [1] Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood, 2010, 116(17):3147-3156.

    [2] D?hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 2010, 115(3):453-474.

    [3] Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol, 2015, 16(9):1025-1036.

    [4] Lamba JK, Chauhan L, Shin M, et al. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase ⅢChildren’s Oncology Group Trial AAML0531. J Clin Oncol, 2017, 35(23):2674-2682.

    [5] Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Ther Adv Hematol, 2018, 9(6):135-148.

    [收稿日期:2020-05-11], 百拇医药(魏志杰)
上一页1 2 3